Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) EBT (2020 - 2025)

Historic EBT for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$56.9 million.

  • 4D Molecular Therapeutics' EBT fell 2968.16% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.1 million, marking a year-over-year decrease of 4583.13%. This contributed to the annual value of -$160.8 million for FY2024, which is 5974.31% down from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' EBT is -$56.9 million, which was down 2968.16% from -$54.6 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' EBT's 5-year high stood at -$7.6 million during Q2 2021, with a 5-year trough of -$56.9 million in Q3 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' median EBT value was -$28.7 million (recorded in 2023), while the average stood at -$31.6 million.
  • Per our database at Business Quant, 4D Molecular Therapeutics' EBT soared by 6070.82% in 2023 and then plummeted by 33416.52% in 2024.
  • Over the past 5 years, 4D Molecular Therapeutics' EBT (Quarter) stood at -$25.1 million in 2021, then dropped by 9.2% to -$27.4 million in 2022, then decreased by 17.86% to -$32.3 million in 2023, then tumbled by 53.85% to -$49.6 million in 2024, then fell by 14.51% to -$56.9 million in 2025.
  • Its EBT stands at -$56.9 million for Q3 2025, versus -$54.6 million for Q2 2025 and -$48.0 million for Q1 2025.